EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Carelabs Co.Ltd (263700) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Carelabs Co.Ltd KRW 6,510, price KRW 2,170, upside +200.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR · ISIN KR7263700007

CC Thin data Sep 24, 2026

Carelabs Co.Ltd

263700 · KQ

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value 6,510 KRW · Strongly undervalued (+200%)
!Quality 58/100
!Weak Growth (revenue 5y +1.3 %/yr)
!Loss over the last twelve months · -8.6% net margin (TTM) · fiscal year 2025 23.5%
!Low debt · negative free cash flow
!Trails peers (3/9)
!Narrow moat 28/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 28 out of 100
Watch Carelabs Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

10,950 KRW 1,613 KRW Fair Value 6,510 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,613 KRW – 10,950 KRW · fair‑value band 4,486 KRW – 9,674 KRW · the 2,170 KRW price screens below the 6,510 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Carelabs Co.Ltd in your weekly email

Every Wednesday you see whether Carelabs Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Carelabs Co.,Ltd operates as a healthcare and beauty care platform company in South Korea. The company offers healthcare IT services, such as hospital information services, hospital customer management software, and digital marketing solutions.

Show more

Carelabs Co.,Ltd operates as a healthcare and beauty care platform company in South Korea. The company offers healthcare IT services, such as hospital information services, hospital customer management software, and digital marketing solutions. It provides BABITALK, a plastic surgery information platform; Medijob, which provides human resources to hospitals; VIBE RC, a digital marketing platform; and BNK Lab that provides dating app services. The company also offers GOODOC, a healthcare integrated platform that allows to search, review, reserve, receive, and follow-up management of various medical services, such as hospitals/pharmacies/beauty based on a mobile environment; and BeautyCon, a multilingual AI molding platform that analyzes user information and usage behavior through artificial intelligence and recommends domestic plastic surgeons, doctors, and procedures suitable for users. In addition, it manufactures and supplies solutions for hospital customers and operation management; develops and distributes health functional foods and nutritional supplements; and develops various customer service solutions, as well as provides IT solutions to pharmacies and hospitals; management consulting, marketing, and medical device distribution services; O2O commerce for beauty tours and concierge services for foreign patients. The company was formerly known as Vibe ALS Corporation and changed its name to Carelabs Co.,Ltd in November 2016. Carelabs Co.,Ltd was founded in 2011 and is based in Seoul, South Korea.

Stock analysis

Carelabs Co.Ltd (263700) currently trades at 2,170 KRW, while our model-based Fair Value estimate is 6,510 KRW, implying the stock looks roughly 66.7% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 19,474 KRW per share, and 10 of the 11 models we run sit above the 2,170 KRW price.

Bear case: the Asset-Based group reads lowest at 2,366 KRW, and 1 of the 11 models stay below the price. Evidence for this calculation is low.

Scenario range: 4,486 KRW (bear) to 9,674 KRW (bull), the price of 2,170 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Carelabs Co.Ltd reported revenue of 81.7B KRW in FY2025 versus 93.9B KRW in FY2021, a compound −3.4%/yr. Reported net income was 19.2B KRW in FY2025, compounding +97.8%/yr from FY2021.

Key figures

Market cap 42.1B KRW (≈ $30.9M) · P/S ratio 0.47 · Dividend yield 1.4% · Net margin 23.5% · Return on equity −7.1% · Return on assets (EBIT) −5.8% · Operating margin 3.3% · Revenue (TTM) 79.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 200%, 263700 screens cheaper than that median.

Fair Value models

Bear 4,486 KRW Fair Value 6,510 KRW Bull 9,674 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 5,936 KRW 8,055 KRW 11,198 KRW 77
EV/EBITDA 2,073 KRW 2,080 KRW 2,088 KRW 67
Growth-Adj P/E 13,632 KRW 19,474 KRW 25,317 KRW 67
All 11 models by family
DCF Models
Owner Earnings 5,936 KRW 8,055 KRW 11,198 KRW 77
Earnings-Based
Graham-Dodd 6,723 KRW 21,885 KRW 29,234 KRW 64
Lynch FV 4,893 KRW 6,990 KRW 9,086 KRW 61
PEG = 1.0 4,893 KRW 6,990 KRW 9,086 KRW 57
Multiples
P/E Multiple 16,312 KRW 21,750 KRW 27,187 KRW 63
P/S Multiple 11,054 KRW 14,739 KRW 18,423 KRW 58
P/B Multiple 11,916 KRW 15,888 KRW 19,860 KRW 55
EV/EBITDA 2,073 KRW 2,080 KRW 2,088 KRW 67
Asset-Based
NCAV (Graham) 1,765 KRW 2,366 KRW 3,531 KRW 54
Economic Profit
Residual Income 6,372 KRW 8,739 KRW 52,428 KRW 64
Growth Earnings
Growth-Adj P/E 13,632 KRW 19,474 KRW 25,317 KRW 67

Open the full fair value analysis →

Notify me when 263700 reaches fair value

Put 263700 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 58 · Market factors (momentum, volatility) 31

Profitability 88
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 71
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 16/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Start year 2020 (pandemic). Over 10 years: +21.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+69.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+68.5%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.69% vs 16%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → −4%
Start year 2020 (pandemic)

Watch 263700, get fair value alerts →

Compare Carelabs Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside +200% · Top 25%
Profitability
Return on assets −2% · Below median
Net margin (TTM) −9% · Below median
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth −11% · Bottom 25%
Dividend yield (TTM) 1.4% · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 4
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 5
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)28 · sector 48

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $270.75 $297.83 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Carelabs Co.Ltd · Fair Value
6,510 KRW +67%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Carelabs Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/263700

Frequently asked questions

Is Carelabs Co.Ltd (263700) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6,510 KRW versus a price of 2,170 KRW, about +200% upside (undervalued).
What is the fair value of 263700?
Our model-based fair value for Carelabs Co.Ltd is 6,510 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,170 KRW.
What is the quality score of 263700?
Carelabs Co.Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Carelabs Co.Ltd (263700)?
Our model-based price target is the fair value of 6,510 KRW (as of Sep 24, 2026) from 11 valuation models. Cautious scenario 4,486 KRW, optimistic scenario 9,674 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Carelabs Co.Ltd stock forecast for 2026?
Our models put fair value at 6,510 KRW, about +200% upside versus a price of 2,170 KRW (undervalued). Cautious scenario 4,486 KRW, optimistic scenario 9,674 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Carelabs Co.Ltd (263700)?
Carelabs Co.Ltd reported trailing-twelve-month revenue of about 79.2B KRW (latest available figure, as of Sep 24, 2026).
Does Carelabs Co.Ltd pay a dividend?
Carelabs Co.Ltd currently shows a dividend yield of about 1.39% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Carelabs Co.Ltd (263700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Carelabs Co.Ltd it is 6,510 KRW per share (as of Sep 24, 2026), against a price of 2,170 KRW. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Carelabs Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 263700 trades below its calculated fair value: price 2,170 KRW, fair value 6,510 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 263700?
No. The price is what the market pays today (2,170 KRW); the fair value is what the company's own numbers justify (6,510 KRW). For Carelabs Co.Ltd the two are 4,340 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Carelabs Co.Ltd worth?
The market values Carelabs Co.Ltd at about 42.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,170 KRW; our models calculate a fair value of 6,510 KRW per share.
What do the bullish and bearish scenarios say about 263700?
Our models span a range for Carelabs Co.Ltd: cautious scenario 4,486 KRW, base 6,510 KRW, optimistic 9,674 KRW per share (as of Sep 24, 2026, price 2,170 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Carelabs Co.Ltd (263700)?
Balance-sheet figures for Carelabs Co.Ltd (as of Sep 24, 2026): return on equity −7.1%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 263700 from its 52-week high?
Carelabs Co.Ltd trades at 2,170 KRW, about 62% below its 52-week high of 5,640 KRW and 35% above the low of 1,613 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 6,510 KRW is for.
Which stocks are comparable to Carelabs Co.Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Carelabs Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,170 KRW, calculated fair value 6,510 KRW (+200%), Quality Score 58/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 263700 calculated?
We run Carelabs Co.Ltd through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6,510 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Carelabs Co.Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Carelabs Co.Ltd (263700)?
The closing price on Sep 23, 2026 was 2,170 KRW. Our model-based fair value is 6,510 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Carelabs Co.Ltd right now?
The price is below even our cautious bear case (4,486 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (4,486 KRW to 9,674 KRW) leaves room in how you read the outcome.

Key figures of Carelabs Co.Ltd

How large is the market capitalisation of Carelabs Co.Ltd (263700)?
The market capitalisation of Carelabs Co.Ltd is 42.1B KRW (≈ $30.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Carelabs Co.Ltd (263700)?
The price-to-sales ratio of Carelabs Co.Ltd is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Carelabs Co.Ltd (263700)?
The dividend yield of Carelabs Co.Ltd is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Carelabs Co.Ltd (263700)?
The net margin of Carelabs Co.Ltd is 23.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Carelabs Co.Ltd (263700)?
The return on equity (ROE) of Carelabs Co.Ltd is −7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Carelabs Co.Ltd (263700)?
On an EBIT basis the return on assets of Carelabs Co.Ltd is −5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Carelabs Co.Ltd (263700)?
The operating margin of Carelabs Co.Ltd is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Carelabs Co.Ltd (263700)?
Revenue at Carelabs Co.Ltd is growing −11.0% versus a year earlier (3y avg −2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Carelabs Co.Ltd (263700)?
Earnings per share at Carelabs Co.Ltd are growing +944% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Carelabs Co.Ltd (263700) generate?
The free cash flow of Carelabs Co.Ltd is −15.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Carelabs Co.Ltd (263700) carry?
The net debt of Carelabs Co.Ltd is 13.2B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Carelabs Co.Ltd in the live analysis

One click puts Carelabs Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.